Free Trial
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

ANI Pharmaceuticals logo
$65.29 +0.07 (+0.11%)
As of 01:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

Key Stats

Today's Range
$63.74
$65.72
50-Day Range
$57.27
$72.95
52-Week Range
$52.50
$77.00
Volume
98,504 shs
Average Volume
312,020 shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.13
Consensus Rating
Buy

Company Overview

ANI Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

ANIP MarketRank™: 

ANI Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 266th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    ANI Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about ANI Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for ANI Pharmaceuticals are expected to grow by 9.07% in the coming year, from $3.86 to $4.21 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ANI Pharmaceuticals is -51.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ANI Pharmaceuticals is -51.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ANI Pharmaceuticals has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ANI Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.44% of the float of ANI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ANI Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in ANI Pharmaceuticals has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ANI Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    ANI Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.44% of the float of ANI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ANI Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in ANI Pharmaceuticals has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ANI Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    6 people have searched for ANIP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $346,854.00 in company stock.

  • Percentage Held by Insiders

    11.10% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ANI Pharmaceuticals' insider trading history.
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead
See More Headlines

ANIP Stock Analysis - Frequently Asked Questions

ANI Pharmaceuticals' stock was trading at $55.28 at the start of the year. Since then, ANIP shares have increased by 18.1% and is now trading at $65.2910.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its earnings results on Friday, May, 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The business's revenue for the quarter was up 43.4% on a year-over-year basis.
Read the conference call transcript
.

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/09/2025
Today
7/03/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$80.13
High Stock Price Target
$94.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+23.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
16.83
P/E Growth
N/A
Net Income
-$18.52 million
Pretax Margin
-4.09%

Debt

Sales & Book Value

Annual Sales
$614.38 million
Cash Flow
$7.76 per share
Price / Cash Flow
8.37
Book Value
$19.11 per share
Price / Book
3.40

Miscellaneous

Free Float
19,258,000
Market Cap
$1.41 billion
Optionable
Optionable
Beta
0.57

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ANIP) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners